Posted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer.
Novartis Pharmaceuticals Canada is pleased to announce that Quebec will now reimburse Kisqali (ribociclib) for eligible patients in combination with an aromatase inhibitor (letrozole) under the province's public drug program for first-line treatment of postmenopausal women living with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
